BellRing Brands (BRBR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Jul, 2026Executive summary
Fiscal 2025 net sales rose 16% to $2.3 billion, with adjusted EBITDA margin at 20.8% and strong volume growth from Premier Protein and Dymatize.
Premier Protein maintained category leadership, achieving record household penetration, repeat rates, and a 26.4% RTD market share.
The RTD shake category remains a high-growth CPG segment, with household penetration at 54% and significant upside potential.
Share repurchases accelerated, with 9 million shares bought back for $473 million (~7% of shares outstanding).
Fiscal 2026 is expected to start soft in Q1 but strengthen in subsequent quarters, with continued innovation and expanded distribution.
Financial highlights
Q4 net sales were $648 million, up 17% year-over-year; adjusted EBITDA was $117 million (18.1% margin).
Adjusted gross profit margin declined to 29.7% in Q4 due to input cost inflation, increased promotions, and packaging redesign.
Premier Protein net sales grew 15% in Q4, with RTD shake sales up 14% and Dymatize net sales up 33%.
Adjusted diluted EPS for the year was $2.17, up 12.4% year-over-year.
Cash from operations was $260.6 million for the year.
Outlook and guidance
Fiscal 2026 net sales guidance: $2.41–$2.49 billion (4%-8% growth); adjusted EBITDA: $425–$455 million (18% margin).
Q1 2026 net sales expected to decline ~5% due to tough comps and non-recurring promotions; acceleration expected from mid-December onward.
Premier Protein expected to deliver high single-digit sales growth at midpoint; Dymatize to see high single-digit sales declines.
Adjusted EBITDA margin expected to decline 280 bps in 2026, mainly from input cost inflation, tariffs, and higher advertising.
Long-term annual net sales growth target updated to 7%-9%; adjusted EBITDA margin target maintained at 18%-20%.
Latest events from BellRing Brands
- Q2 net sales up 19% with Premier Protein driving record growth; FY2025 outlook reaffirmed.BRBR
Q2 20259 Jul 2026 - Premier Protein drove strong sales and EBITDA growth, with double-digit 2025 outlook despite margin pressures.BRBR
Q4 20248 Jul 2026 - Net sales up 1% to $537.3M, margins fell, 2026 outlook narrowed, CEO transition and settlements announced.BRBR
Q1 20268 Jul 2026 - Net sales and earnings surged, guidance raised, and Premier Protein drove record growth.BRBR
Q3 20248 Jul 2026 - Q2 sales rose 2% but margins and earnings fell sharply amid inflation and inventory charges.BRBR
Q2 20265 May 2026 - All proposals passed with strong support and no shareholder questions were raised.BRBR
AGM 20263 Feb 2026 - Q1 net sales up 24% and net earnings up 75%, with FY25 outlook raised on Premier Protein strength.BRBR
Q1 20258 Jan 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay; online access promoted.BRBR
Proxy Filing16 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve pay, with focus on governance and ESG.BRBR
Proxy Filing16 Dec 2025